Large Korean Study Tracks Real-World Safety of Hormone Therapy in 4,000 Women

This comprehensive post-marketing surveillance study examined the real-world safety and effectiveness of Angeliq hormone replacement therapy in postmenopausal Korean women. The research aimed to gather practical data about how this estradiol and drospirenone combination performed outside controlled clinical trial conditions.

The study employed a non-interventional, prospective, multi-center design spanning five years from 2007 to 2012. Researchers enrolled 4,078 postmenopausal women across multiple Korean medical centers, targeting an initial goal of 4,500 participants. Unlike randomized controlled trials, this observational approach captured real-world treatment patterns and outcomes.

Participants received Angeliq therapy as prescribed by their physicians for approved indications including menopausal symptom management and osteoporosis prevention. The surveillance monitored both therapeutic benefits and adverse events occurring during routine clinical practice, providing regulatory authorities with post-market safety data.

This completed study generated valuable insights into hormone replacement therapy outcomes in an Asian population, where genetic and lifestyle factors may influence treatment responses differently than in Western populations. The large sample size and extended monitoring period strengthened the reliability of safety and efficacy findings.

For longevity-focused individuals, this research contributes important real-world evidence about hormone therapy's risk-benefit profile in postmenopausal women. The findings help inform decisions about hormone replacement as a strategy for managing age-related hormonal decline, bone health maintenance, and quality of life optimization during the postmenopausal transition period.